Hepatitis C and interferon-associated retinopathy: A case report

Ann M. Van Wie O.D.
{"title":"Hepatitis C and interferon-associated retinopathy: A case report","authors":"Ann M. Van Wie O.D.","doi":"10.1016/j.optm.2010.11.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span><span><span><span>Hepatitis C is a common virus affecting approximately 170 million people worldwide. The main ocular manifestations of </span>hepatitis C virus include a Sjögren-type of dry eye syndrome and an ischemic </span>retinopathy<span> secondary to treatment with </span></span>interferon<span> or a result of a systemic vasculitis induced by the infection itself. Current treatment for hepatitis C is a combination therapy using pegylated (long-lasting) interferon and </span></span>ribavirin<span><span>. This treatment, however, is not without ocular sequelae. Interferon-associated retinopathy is present in &gt; 50% of patients taking the </span>drug<span><span> and is mainly characterized by cotton wool spots and </span>retinal hemorrhages. The pathogenesis of this disorder is not specifically known. Fortunately, many patients remain asymptomatic, and the retinal changes are usually reversible.</span></span></p></div><div><h3>Case Report</h3><p>A 48-year-old black man presented to the clinic complaining of decreased vision in both eyes for the previous few weeks. His medical history was positive for hypertension and hepatitis C for which he was being treated. At his examination, he had interferon retinopathy diagnosed. Soon thereafter, his treatment for hepatitis C was discontinued, and when he returned for follow-up 4 months later, his retinal findings had resolved.</p></div><div><h3>Conclusions</h3><p>An overview of hepatitis C and its recommended therapy and possible ocular side effects are reviewed, as well as the differential diagnosis of interferon-associated retinopathy, 1 of the main side effects of treatment.</p></div>","PeriodicalId":51265,"journal":{"name":"Optometry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.optm.2010.11.016","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Optometry","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1529183911005033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Background

Hepatitis C is a common virus affecting approximately 170 million people worldwide. The main ocular manifestations of hepatitis C virus include a Sjögren-type of dry eye syndrome and an ischemic retinopathy secondary to treatment with interferon or a result of a systemic vasculitis induced by the infection itself. Current treatment for hepatitis C is a combination therapy using pegylated (long-lasting) interferon and ribavirin. This treatment, however, is not without ocular sequelae. Interferon-associated retinopathy is present in > 50% of patients taking the drug and is mainly characterized by cotton wool spots and retinal hemorrhages. The pathogenesis of this disorder is not specifically known. Fortunately, many patients remain asymptomatic, and the retinal changes are usually reversible.

Case Report

A 48-year-old black man presented to the clinic complaining of decreased vision in both eyes for the previous few weeks. His medical history was positive for hypertension and hepatitis C for which he was being treated. At his examination, he had interferon retinopathy diagnosed. Soon thereafter, his treatment for hepatitis C was discontinued, and when he returned for follow-up 4 months later, his retinal findings had resolved.

Conclusions

An overview of hepatitis C and its recommended therapy and possible ocular side effects are reviewed, as well as the differential diagnosis of interferon-associated retinopathy, 1 of the main side effects of treatment.

丙型肝炎和干扰素相关视网膜病变1例报告
丙型肝炎是一种常见的病毒,影响着全世界约1.7亿人。丙型肝炎病毒的主要眼部表现包括Sjögren-type干眼综合征和继发于干扰素治疗或由感染本身引起的全身血管炎的缺血性视网膜病变。目前丙型肝炎的治疗是使用聚乙二醇化(长效)干扰素和利巴韦林的联合治疗。然而,这种治疗并非没有眼部后遗症。干扰素相关性视网膜病变存在于>50%的患者服用该药,主要表现为棉絮斑和视网膜出血。这种疾病的发病机制尚不清楚。幸运的是,许多患者仍然无症状,视网膜的改变通常是可逆的。病例报告一名48岁黑人男子前来就诊,主诉前几周双眼视力下降。他的病史呈高血压和丙型肝炎阳性,他正在接受治疗。在检查中,他被诊断为干扰素视网膜病变。此后不久,他的丙型肝炎治疗停止,4个月后,当他返回随访时,他的视网膜病变已经消失。结论综述了丙型肝炎的概况及其推荐治疗方法和可能的眼部副作用,以及干扰素相关性视网膜病变的鉴别诊断,干扰素相关性视网膜病变是治疗的主要副作用之一。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Optometry
Optometry OPHTHALMOLOGY-
自引率
0.00%
发文量
0
审稿时长
>12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信